Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.41 |
| ▸ | GNRHR | P30968 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1729766 | 1.00 | SLC6A2 (0.41) | SLC6A2GNRHRTRPM8GPR139SLC7A5 | |
| SCHEMBL12261520 | 1.00 | SLC6A2 (0.41) | SLC6A2GNRHRTRPM8GPR139SLC7A5 | |
| Hydrochloric Acid SCHEMBL21272610 | 0.98 | SLC6A2 (0.42) | SLC6A2GNRHRTRPM8 | |
| Hydrochloric Acid SCHEMBL29440446 | 0.98 | SLC6A2 (0.42) | SLC6A2GNRHRTRPM8 | |
| Hydrochloric Acid SCHEMBL16563565 | 0.98 | SLC6A2 (0.42) | SLC6A2GNRHRTRPM8 | |
| SCHEMBL21288062 | 0.88 | CETP (0.41) | SLC6A2GNRHRTRPM8GPR139 | |
| SCHEMBL22965301 | 0.86 | TACR1 (0.40) | SLC6A2GNRHR | |
| SCHEMBL22952644 | 0.86 | TACR1 (0.40) | SLC6A2GNRHR | |
| SCHEMBL734938 | 0.85 | KIF11 (0.43) | SLC6A2TRPM8SLC7A5 | |
| SCHEMBL1730276 | 0.85 | CETP (0.43) | SLC6A2GNRHRSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4241843-A2 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. Lundbeck A/S (DK) | 2023-09-13 | — | — | EP | disclosed |
| EP-3755684-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| US-11548849-B2 | Alcohol derivatives as KV7 potassium channel openers | H. LUNDBECK A/S (DK) | 2023-01-10 | — | — | US | disclosed |
| WO-2021023617-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2021-02-11 | — | — | WO | disclosed |
| WO-2021023616-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES | H. LUNDBECK A/S (DK) | 2021-02-11 | — | — | WO | disclosed |
| US-20210032196-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2021-02-04 | — | — | US | disclosed |
| US-20200172474-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2020-06-04 | — | — | US | disclosed |
| WO-2019161877-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2019-08-29 | — | — | WO | disclosed |
| US-20190256456-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2019-08-22 | — | — | US | disclosed |
| EP-2036881-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 1-(FLUORO-, TRIFLUOROMETHYL- OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVE | CENTRAL GLASS CO LTD (JP) | 2013-09-25 | — | — | EP | disclosed |
| EP-1530562-B1 | OPTICALLY ACTIVE 1-(FLUORO-,TRIFLUOROMETHYL-OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVES AND PROCESS FOR PRODUCING SAME | CENTRAL GLASS CO LTD (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-7985880-B2 | Method for producing optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy-substituted phenyl) alkylamine N-monoalkyl derivative | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-07-26 | — | — | US | disclosed |
| US-20090326272-A1 | Method for Producing Optically Active 1-(Fluoro-, Trifluoromethyl- or Trifluoromethoxy-Substituted Phenyl) Alkylamine N-Monoalkyl Derivative | CENTRAL GLASS COMPANY, LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2036881-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 1-(FLUORO-, TRIFLUOROMETHYL- OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVE | Central Glass Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-7368609-B2 | Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20070142670-A1 | Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same | CENTRAL GLASS CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| US-7186865-B2 | Reacting optically active secondary amine with alkylation agent in presence of a base, thereby converting the secondary amine into an optically active tertiary amine and subjecting the tertiary amine to hydrogenolysis, producing the N-monoalkyl derivative; intermediates for drugs, agriculture | CENTRAL GLASS COMPANY, LIMITED (JP) | 2007-03-06 | — | — | US | disclosed |
| US-20040235961-A1 | Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326272-A1 | Method for Producing Optically Active 1-(Fluoro-, Trifluoromethyl- or Trifluoromethoxy-Substituted Phenyl) Alkylamine N-Monoalkyl Derivative | NAT1, MAOA, HNMT | SLC6A2 1353/4885GNRHR 3462/4885TRPM8 1486/4885 |
| US-11548849-B2 | Alcohol derivatives as KV7 potassium channel openers | KCNA7, KCNK17, KCNAB1 | SLC6A2 452/4885GNRHR 3478/4885TRPM8 82/4885 |
| US-20040235961-A1 | Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same | NAT1, PNMT, AFF1 | SLC6A2 1673/4885GNRHR 3421/4885TRPM8 2384/4885 |
| US-20190256456-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | KCNA7, KCNK17, KCNQ1 | SLC6A2 396/4885GNRHR 3573/4885TRPM8 65/4885 |
| US-20210032196-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | KCNA7, KCNK17, KCNQ1 | SLC6A2 396/4885GNRHR 3573/4885TRPM8 65/4885 |
| US-20200172474-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | KCNA7, KCNK17, KCNQ1 | SLC6A2 396/4885GNRHR 3573/4885TRPM8 65/4885 |
| US-20070142670-A1 | Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same | NAT1, AFF1, PNMT | SLC6A2 1872/4885GNRHR 2682/4885TRPM8 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.